Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vivo.
about
Low-intensity continuous ultrasound triggers effective bisphosphonate anticancer activity in breast cancer.Bisphosphonates and bone quality.Intermittent Ibandronate Maintains Bone Mass, Bone Structure, and Biomechanical Strength of Trabecular and Cortical Bone After Discontinuation of Parathyroid Hormone Treatment in Ovariectomized Rats.Effect of Sequential Treatment with Bisphosphonates After Teriparatide in Ovariectomized Rats: A Direct Comparison Between Risedronate and Alendronate.Alpha C-telopeptide of type I collagen is associated with subchondral bone turnover and predicts progression of joint space narrowing and osteophytes in osteoarthritis.New bone formation and microstructure assessed by combination of confocal laser scanning microscopy and differential interference contrast microscopy.Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study.Mandibular inferior cortical bone thickness on panoramic radiographs in patients using bisphosphonates.Mechanical competence of ovariectomy-induced compromised bone after single or combined treatment with high-frequency loading and bisphosphonates.Non-Ototoxic Local Delivery of Bisphosphonate to the Mammalian Cochlea.Bisphosphonate uptake in areas of tooth extraction or periapical diseaseEquilibrium-dependent bisphosphonate interaction with crystalline bone mineral explains anti-resorptive pharmacokinetics and prevalence of osteonecrosis of the jaw in rats.Difference in Bone Mineral Density Change at the Lateral Femoral Cortices according to Administration of Different Bisphosphonate Agents.Fluorescent Bisphosphonate and Carboxyphosphonate Probes: A Versatile Imaging Toolkit for Applications in Bone Biology and Biomedicine.Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis.Age- and menopause-related bone loss compromise cortical and trabecular microstructure.Co-administration of antiresorptive and anabolic agents: a missed opportunity.Bone-Seeking Matrix Metalloproteinase-2 Inhibitors Prevent Bone Metastatic Breast Cancer Growth.Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironmentProtective effect of low-dose risedronate against osteocyte apoptosis and bone loss in ovariectomized rats.Development of oral osteomucosal tissue constructs in vitro and localization of fluorescently-labeled bisphosphonates to hard and soft tissue.Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naïve or on long-term alendronate therapy.Reverse Microemulsion-Based Synthesis of (Bis)phosphonate-Metal Materials with Controllable Physical Properties: An Example Using Zoledronic Acid-Calcium Complexes.Removal of matrix-bound zoledronate prevents post-extraction osteonecrosis of the jaw by rescuing osteoclast function.In vivo distribution of zoledronic acid in a bisphosphonate-metal complex-based nanoparticle formulation synthesized by a reverse microemulsion method.Osteocytes: regulating the mineral reserves?Risedronate improves bone architecture and strength faster than alendronate in ovariectomized rats on a low-calcium diet.Risedronate slows or partly reverses cortical and trabecular microarchitectural deterioration in postmenopausal women.No reduction in circulating preosteoclasts 18 months after treatment with zoledronate: analysis from a randomized placebo controlled trial.
P2860
Q27306861-0432083B-65CE-4ACB-83F3-68AC9AFFA39AQ33683219-A03EC50D-1F09-4A47-A0FF-9EB9EA8D4A74Q33841826-889A000F-7D1E-4D59-8F1E-FB6F4890D1B0Q33841863-AA7CB740-E1D7-48F7-9AA2-1E6CBACAEE8BQ34122276-2D888F23-3917-483C-A1D8-7A11053BAEE8Q35047187-587498F3-C35F-4079-82A2-17FDBBE55B82Q35215353-EFFAC36A-B54D-4C9E-A786-3A332251FB3DQ35400080-81495E6E-1591-40DD-A1E9-49FD023F4564Q35669754-4642CECC-509F-45C1-8309-8E1E55CB7093Q35748623-CA73186C-7D84-4E96-80FB-A247745763AEQ35755688-851952BF-499C-458E-AD88-81B6E89FF81CQ36553571-F10D9B38-9D7C-4A20-8E86-C46A06C90097Q36989638-75792D05-C862-47EC-9885-4010F715F4B1Q37425779-EFD9536A-9471-41CE-B65D-32DF069BD263Q37661855-C6D313F5-182F-4128-91CD-C5E20700088EQ38119928-39FD44E3-738A-4D96-8176-C113ABBBB62DQ38367370-BCD92944-370A-4BFF-ABA3-0284537D68BFQ38722186-F7FFDC82-8187-481F-AA16-FFC2E278CCE3Q38726989-1B4605D7-76D9-43DA-9856-014EF9448CE1Q42680625-0A00EF9B-2BC5-4B4B-8952-F6C47417ED4DQ42733035-EDF72138-6134-48AF-AA60-4F5CE6ED1760Q46284190-C65B6C2D-E61C-43C3-BA95-EDAA243454EAQ48172723-356581D7-3233-4230-AFE2-570C759F1C2FQ48510488-E81D55F3-1575-4244-8A7F-993C04D75B3DQ50691033-C4371FD8-F4A1-42AB-831D-F9BF76308D03Q50713021-C7080C2E-1A77-44B9-B709-58618E5AA41AQ51174684-FB65B567-0C90-45F0-B664-24AB5B8002BCQ53092377-5B6AE674-0319-4582-9A9F-05874AE8B871Q53357832-771E0854-95A9-44E4-A6D4-E86A95C8F9B5
P2860
Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vivo.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Influence of bone affinity on ...... beled bisphosphonates in vivo.
@en
Influence of bone affinity on ...... beled bisphosphonates in vivo.
@nl
type
label
Influence of bone affinity on ...... beled bisphosphonates in vivo.
@en
Influence of bone affinity on ...... beled bisphosphonates in vivo.
@nl
prefLabel
Influence of bone affinity on ...... beled bisphosphonates in vivo.
@en
Influence of bone affinity on ...... beled bisphosphonates in vivo.
@nl
P2093
P2860
P50
P356
P1476
Influence of bone affinity on ...... abeled bisphosphonates in vivo
@en
P2093
Anke J Roelofs
Boris A Kashemirov
Charles E McKenna
Charlotte A Stewart
Frank H Ebetino
Fraser P Coxon
Mark W Lundy
Shuting Sun
P2860
P304
P356
10.1002/JBMR.1543
P577
2012-04-01T00:00:00Z